Dental Implant Technology
We believe that the key innovations in the future of dental implants are in the field of nanotechnology; specifically, to enhance rapid
healing of implants and reduce failure rates as well as patient discomfort.
The greatest risk of failure of a dental implant is during the osseo-integration phase, or when the bone adopts the implant and bone
tissue grow in close proximity to the metal implant. It has been found in numerous studies that when the surfaces immediately adjacent to the
bone tissue are nano-structured, the rate of osteo-integration is increased and the time required for the implant to be integrated into the bone
tissue is cut down significantly. The benefits of such technology extend to both dental professionals and patients. For one, it represents a
significant advantage for all patients since the time it takes to heal would be cut down significantly and the implant could be used far sooner.
Also, this would help dentists contain costs on failed implants and further reduce the overhead associated with patients’ “chair time,” which is
not always fully recovered if there are too many visits required to execute any given procedure.
We have developed a unique solution to the problem of how to nano-structure a dental implant and speed up the healing time. Using
Cold-War technology originally developed for the nuclear weapons program, we can create a favorable nano-texturing effect right at the surface
of dental implants – precisely where it is needed.
We are in discussions with Omega Ti Implants of Albuquerque-NM (“Omega Ti”) and Alpha Omega Power Technologies of
Albuquerque-NM to enter into a joint venture. In connection therewith, a new entity, named Osseostat, LLC, was formed for the sole purpose of
commercializing our patent-pending rapid – healing dental implant technology. The earliest we expect to commercialize such technology is
fourth quarter of 2012, although there is no assurance that it will be commercialized at all. Omega Ti has already received approval from the
United States Food and Drug Administration in connection with its nano-structure implants for human use — a technology related to our patentpending dental implant technology. They have conducted trials on material where the entire implant was made up of nano-grains. This material
is very expensive, however, and there is currently no reliable source for bulk quantities. As such, our method of just "nano-texturing" the surface
is particularly attractive since it could potentially be used on any implant made by any implant manufacturer (as long as it is titanium).
Also, other prosthetic markets exist beyond dental implants including hips, knees, and the plethora of smaller titanium components such
as plates, screws, and other devices used to reconstruct bones or joints after either serious injury or natural aging. Through this innovative and
advanced materials processing technology, we expect to significantly impact the dental implant market first, and then grow the business to
include other bio-prosthetic devices that could benefit from rapid bone healing. Omega Ti has undertaken initial marketing efforts and sales
campaigns in India as well since the Asian markets for implants represents the fastest growing sector of the market worldwide. Through our
partnership with Omega Ti, we would anticipate access to the Chinese, Indian, Korean and Taiwanese markets Omega Ti plans to penetrate, as
well as utilize Omega Ti’s existing domestic distribution channels.
Working with Omega Ti, we are currently performing pre-clinical evaluations of our dental implants in Canada. The results so far have
shown that our implants are able to fully integrate with the human jaw in a period of four weeks. We are also in discussions with the University
of New Mexico about the planning and performance of a human clinical trial. This would be an important step towards the full
commercialization and approval of our medical device for sale in the United States, North America, Europe, and Asia. We expect the clinical
trial to be underway by the third quarter of 2012.